Clinical Trials Logo

Clinical Trial Summary

This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Neoplasms
  • Relapsed or Refractory Solid Tumors

NCT number NCT01778439
Study type Interventional
Source Mereo BioPharma
Contact
Status Completed
Phase Phase 1
Start date February 2013
Completion date July 2016

See also
  Status Clinical Trial Phase
Terminated NCT02963610 - Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT04447755 - A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) Phase 2